Press Releases Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
39.91 ^USD	+0.23%		+3.47%	+7.98%

Apr. 25	Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	CI
Apr. 18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mahesh Krishnan Elected to Halozyme's Board of Directors	Apr. 25	PR
Halozyme to Report First Quarter 2024 Financial and Operating Results	Apr. 23	PR
Halozyme to Participate in Upcoming Investor Conferences	Feb. 27	PR
Halozyme Therapeutics: Q4 Earnings Snapshot	Feb. 20	AQ
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	Feb. 20	PR
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	Feb. 08	PR
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 30	AQ
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Jan. 29	PR
Halozyme Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for Generalized Myasthenia Gravis	Jan. 19	AQ
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis	Jan. 18	PR
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Jan. 16	PR
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types	Jan. 16	PR
Halozyme to Host Investor Business Forum and Long-Term Outlook Call	Jan. 15	AQ
Halozyme to Host Investor Business Forum and Long-Term Outlook Call	Jan. 12	PR
Halozyme to Present at Upcoming Investor Conferences	Nov. 27	PR
Halozyme Announces argenx Receives European Commission Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis	Nov. 17	AQ
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis	Nov. 16	PR
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's disease	Nov. 07	AQ
Halozyme Therapeutics: Q3 Earnings Snapshot	Nov. 06	AQ
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS	Nov. 06	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Press Releases

Filters